Barclays Maintains Overweight on bluebird bio, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on bluebird bio (NASDAQ:BLUE) but lowers the price target from $8 to $4.
August 15, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on bluebird bio but lowers the price target from $8 to $4.
The lowered price target from $8 to $4 suggests a less optimistic outlook for bluebird bio's stock performance, which could lead to a short-term decline in its stock price despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100